DL-leucylglycine methyl ester hydrochloride | 120746-40-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: DL-leucylglycine methyl ester hydrochloride
• 英文别名: N-DL-leucyl-glycine methyl ester; hydrochloride；N-DL-Leucyl-glycin-methylester; Hydrochlorid；Methyl 2-[(2-amino-4-methylpentanoyl)amino]acetate;hydrochloride
• CAS: 120746-40-9
• 化学式: C₉H₁₈N₂O₃*ClH
• 分子量: 238.714
• InChiKey: FFNQRPZQQZRNQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.07
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  81.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,3-二溴丙酸甲酯 、 DL-leucylglycine methyl ester hydrochloride 在 三乙胺 作用下， 反应 14.0h， 以80%的产率得到Methyl 1-[1-[(2-methoxy-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]aziridine-2-carboxylate
  参考文献：
  名称：

  Amino acid derivatives of aziridine

  摘要：

  DOI：

  10.1007/bf00506610

文献信息

• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS D'HISTONE-DÉSACÉTYLASES
  申请人：BROAD INST INC

  公开号：WO2014018979A1

  公开（公告）日：2014-01-30

  The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting β-cells and improving insulin resistence. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation. Compounds of the invention are useful for treating, alleviating, and/or preventing various conditions, including for example, a metabolic disorder such as type 1 or type 2 diabetes, dyslipidemias, lipodystrophies, liver disease associated with metabolic syndrome, polycystic ovarian syndrome, or obesity; inflammatory disease; neurological disorder; a memory or cognitive function disorder/impairment; an extinction learning disorder; fungal disease or infection; viral disease or infection such as HIV; hematological disease; liver disease; lysosomal storage disease; or neoplastic disease in humans or animals.

  本发明涉及式(I)的化合物或其药学上可接受的盐、水合物、溶剂合物或前药，其中X1、X2、X3、X4、X5、W1、W2、W3和W4如所述。本发明一般涉及组织脱乙酰化酶抑制剂以及制备和使用它们的方法。在一个方面，该发明涉及选择性HDAC3抑制剂，可用于保护β细胞并改善胰岛素抵抗。选择性HDAC3抑制剂还可用于促进认知功能，增强学习和记忆形成。本发明的化合物可用于治疗、缓解和/或预防各种疾病，例如代谢紊乱，如1型或2型糖尿病、血脂异常、脂肪萎缩、与代谢综合征相关的肝病、多囊卵巢综合征或肥胖症；炎症性疾病；神经系统疾病；记忆或认知功能障碍；消除学习障碍；真菌疾病或感染；病毒性疾病或感染，如艾滋病病毒；血液病；肝病；溶酶体贮积病；或人类或动物的肿瘤性疾病。
• COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER
  申请人：KDAc Therapeutics, Inc.

  公开号：US20190216754A1

  公开（公告）日：2019-07-18

  Aspects of the disclosure relate to compositions, kits, and methods for the treatment of cancer that utilize a selective histonc deacetylase 3 (HDAC3) inhibitor. In some aspects, the compositions, kits, and methods relate to use of a selective HDAC3 inhibitor in combination with an immunotherapy agent (e.g., an immune checkpoint inhibitor).

  披露的方面涉及使用选择性组蛋白去乙酰化酶3（HDAC3）抑制剂进行癌症治疗的组合物、试剂盒和方法。在某些方面，这些组合物、试剂盒和方法涉及使用选择性HDAC3抑制剂与免疫治疗药物（例如免疫检查点抑制剂）的结合。
• Inhibitors of Histone Deacetylase
  申请人：The Broad Institute, Inc.

  公开号：US20140080800A1

  公开（公告）日：2014-03-20

  The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R 2a , R 2b , R 2c , R 5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.

  本发明涉及式（I）的化合物：或其药学上可接受的盐、水合物、溶剂合物或前药，其中U、J、V、X、R2a、R2b、R2c、R5和t如本文所述。本发明通常涉及组织脱乙酰化酶抑制剂及其制备和使用方法。这些化合物有助于促进认知功能和增强学习和记忆形成。此外，这些化合物对于治疗、缓解和/或预防各种疾病有用，包括但不限于神经系统疾病、记忆和认知功能障碍、消退学习障碍、真菌病和感染、炎症性疾病、血液病和动物的肿瘤疾病。
• FLUORESCENT SUBSTRATES FOR DETERMINING LYSINE MODIFYING ENZYME ACTIVITY
  申请人：The Broad Institute, Inc.

  公开号：US20140335550A1

  公开（公告）日：2014-11-13

  The invention relates to a compound of Formula I: F 1 -X 1 -L 1 -X 2 -P 1 -X 3 -G 1 (Formula I).

  本发明涉及一种化合物，其化学式为F1-X1-L1-X2-P1-X3-G1（化学式I）。
• INHIBITORS OF HISTONE DEACETYLASE
  申请人：The General Hospital Corporation d/b/a Massachusetts General Hospital

  公开号：US20150191427A1

  公开（公告）日：2015-07-09

  The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X 1 , X 2 , X 3 , X 4 , X 5 , W 1 , W 2 , W 3 , and W 4 are as described. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting β-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation. Compounds of the invention are useful for treating, alleviating, and/or preventing various conditions, including for example, a metabolic disorder such as type 1 or type 2 diabetes, dyslipidemias, lipodystrophies, liver disease associated with metabolic syndrome, polycystic ovarian syndrome, or obesity; inflammatory disease; neurological disorder; a memory or cognitive function disorder/impairment; an extinction learning disorder; fungal disease or infection; viral disease or infection such as HIV; hematological disease; liver disease; lysosomal storage disease; or neoplastic disease in humans or animals.

  本发明涉及公式(I)的化合物或其药学上可接受的盐、水合物、溶剂物或前药，其中X1、X2、X3、X4、X5、W1、W2、W3和W4如所述。本发明通常涉及组织脱乙酰化酶抑制剂及其制备和使用方法。在一个方面，本发明涉及选择性HDAC3抑制剂，用于保护β细胞和改善胰岛素抵抗力。选择性HDAC3抑制剂还有助于促进认知功能和增强学习和记忆形成。本发明的化合物可用于治疗、缓解和/或预防各种疾病，包括代谢紊乱，例如1型或2型糖尿病、脂质代谢异常、脂肪萎缩症、代谢综合征相关的肝病、多囊卵巢综合征或肥胖症；炎症性疾病；神经系统疾病；记忆或认知功能障碍；灭绝学习障碍；真菌疾病或感染；病毒性疾病或感染，如HIV；血液学疾病；肝脏疾病；溶酶体贮积病；或动物中的肿瘤性疾病。